Modality
Peptide
MOA
HER2
Target
DLL3
Pathway
NF-κB
Huntington's
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
Phase 1Current
NCT04259098
970 pts·Huntington's
2019-01→TBD·Terminated
970 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2019
P1
Termina…
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04259098 | Phase 1 | Huntington's | Terminated | 970 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |